Women who feel more fatigued and have higher levels of SHBG during chemotherapy are more likely to gain weight, indicating that fatigue and hormone-binding proteins may play a role in weight gain.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could determine whether fatigue and SHBG consistently predict weight gain across studies and whether interventions targeting these factors reduce weight gain.
A systematic review and meta-analysis of all prospective studies measuring fatigue (validated scales) and SHBG levels in breast cancer patients during chemotherapy, with weight change as outcome, including at least 15 studies with >3,000 total participants and standardized adjustment for age, BMI, and estrogen levels.
An RCT could test whether reducing fatigue (e.g., via exercise or cognitive behavioral therapy) or modulating SHBG (e.g., via estrogen suppression) reduces weight gain.
A double-blind RCT of 400 breast cancer patients randomized to receive either a 12-week supervised exercise program targeting fatigue reduction or standard care, with SHBG measured at baseline and end, and weight change as primary outcome, stratified by baseline SHBG levels.
A prospective cohort could confirm whether fatigue and SHBG levels at mid-treatment predict later weight gain, adjusting for physical activity and diet.
A prospective cohort of 500 patients, with weekly fatigue scores (PROMIS), monthly SHBG, physical activity (accelerometry), and dietary intake measured from diagnosis to 6 months, using multivariate models to assess predictive power of fatigue and SHBG for weight gain.
A case-control study could compare fatigue and SHBG levels between patients who gained >5 lb and those who did not, to identify thresholds of risk.
A matched case-control study comparing 100 patients with >5 lb weight gain to 100 with <1 lb gain, measuring fatigue severity and SHBG levels at mid-chemotherapy to determine if these factors distinguish weight gain groups.
A cross-sectional study could estimate the association between fatigue and SHBG with weight gain at a single time point after chemotherapy.
A survey of 3,000 breast cancer survivors measuring current fatigue, SHBG, and weight, asking whether they received chemotherapy and when, to assess cross-sectional associations.